HPV Screening for Women 65 and Older Evidence on Testing Self Sampling and Tailored Care
- OBGYN Library Team
- Aug 26
- 8 min read
A 65th birthday does not automatically remove cervical cancer risk. For many women, screening can safely stop after 65, but only when past results show a clear pattern of low risk. For others, especially those who were never screened, screened irregularly, or have unknown records, testing after 65 can still prevent disease.
Human papillomavirus, better known as HPV, sits at the centre of this decision. Nearly all cervical cancers are linked to persistent infection with high-risk HPV types. That makes HPV-based testing a powerful tool, including for older women who may not fit neatly into age-based screening rules.
This article explains what the evidence says about HPV testing, self-sampling, and tailored screening for women aged 65 and older. It is informational only and should not replace medical advice from a qualified clinician.
Why HPV still matters after 65
HPV is common, and most infections clear on their own. The concern is persistent high-risk HPV, which can cause cell changes in the cervix over many years. If those changes are not found and treated, some may progress to cancer.
For women over 65, HPV risk has a few features that can make screening decisions more complex.
Some older women acquired HPV earlier in life, and the infection may have persisted at low levels. In some cases, HPV that was not detectable for years may become detectable again later, possibly due to changes in immune control with age. Others may have new exposure through later-life relationships. These patterns mean a positive HPV result in an older woman is not always a “new” infection, but it still deserves appropriate follow-up.
Age also changes the cervix. After menopause, the transformation zone, the area where most cervical cancers begin, often moves higher into the cervical canal. This can make sampling harder during a clinician-collected test and may affect cytology, also called the Pap smear. Vaginal dryness, discomfort during pelvic examination, prolapse, mobility issues, and past trauma can also make speculum-based screening difficult.
That is one reason HPV-based approaches are gaining attention. They can detect the underlying viral risk before visible cell changes appear. In the context of CERVICAL CANCER SCREENING, this shift from looking mainly for abnormal cells to looking for high-risk HPV has changed how many programmes think about prevention.
When screening after 65 may still be needed
Many guidelines allow screening to stop after 65 when a woman has had enough recent negative results and no history of significant cervical precancer. The exact rules vary by country and programme, but the principle is consistent: stopping is safest when prior screening confirms low risk.
Screening after 65 may still be appropriate when there is:
No screening history or unclear records
Long gaps between past tests
A previous high-grade cervical lesion
Exposure to diethylstilbestrol before birth, where relevant
Immunosuppression, including HIV or long-term immune-suppressing medicines
A cervix still present after hysterectomy, or uncertainty about whether the cervix was removed
New symptoms such as postmenopausal bleeding, which needs diagnostic evaluation rather than routine screening
A key point often gets missed. Screening is for people without symptoms. Bleeding after sex, postmenopausal bleeding, unexplained discharge, or pelvic pain should be assessed clinically, even if a recent screening test was normal.
What systematic reviews say about HPV-based testing
Recent systematic reviews and meta-analyses have consistently supported HPV-based testing as a highly sensitive method for detecting women at risk of cervical precancer and cancer. Across many screening settings, HPV testing tends to find more high-grade precancerous lesions than cytology alone.
That higher sensitivity matters in older women. A negative high-risk HPV test gives strong reassurance because cervical cancer is unlikely without persistent high-risk HPV. This is why many screening programmes use longer intervals after a negative HPV test than after cytology alone.
The trade-off is that HPV testing can identify infections that may not lead to cancer. In younger women, this is a major issue because HPV is very common and often temporary. In older women, HPV prevalence is generally lower than in younger age groups, so a positive result may carry more weight. Still, a positive HPV test is not a cancer diagnosis. It is a signal that follow-up is needed.
Systematic reviews comparing screening strategies generally point to three practical findings:
HPV testing is more sensitive than cytology alone
It is better at identifying people who may have or later develop high-grade cervical changes.
Cytology can remain useful as triage
When HPV is positive, cytology can help decide who needs immediate colposcopy and who can be retested.
Genotyping can sharpen risk assessment
HPV types 16 and 18 carry the highest cancer risk. Identifying these types can help prioritise follow-up.
For older women, this evidence supports HPV-based screening, but not as a one-size-fits-all test. The result has to be interpreted alongside screening history, health status, and the ability to complete follow-up.
What self-sampling adds for older women
Self-sampling allows a woman to collect a vaginal sample herself, usually with a swab or small brush, which is then tested for high-risk HPV. It does not require a speculum examination.
This matters because many older women face barriers to clinic-based cervical sampling. These barriers may include discomfort, embarrassment, difficulty travelling, caring responsibilities, disability, lack of privacy, or previous negative healthcare experiences. Some women simply stop attending because they believe screening is no longer relevant after menopause.
Self-sampling can reduce these barriers. It may be done at home or in a clinic setting, depending on the programme. It can also be offered by community health workers in some settings, with clear instructions and safe sample transport.
Recent systematic reviews and meta-analyses have found that self-sampling can increase participation among women who are under-screened or never-screened. This is one of its strongest advantages. A test only prevents cancer if people can actually access and complete it.
The accuracy of self-sampling depends on the HPV assay used. Reviews have generally found that PCR-based HPV tests on self-collected vaginal samples perform close to clinician-collected samples for detecting high-grade cervical disease. Some older test methods may perform less well on self-collected samples, so programmes need to choose validated assays.
Self-sampling also has limits. A positive result still requires follow-up. That may mean clinician-collected cytology, genotyping-based triage, repeat HPV testing, or colposcopy. If health systems offer self-sampling but cannot ensure follow-up, the benefit drops.
HPV testing compared with cytology in older age
Cytology has saved many lives, but it has known limitations. It depends on collecting enough cells from the right area and on accurate laboratory interpretation. In postmenopausal women, samples may be harder to interpret because of atrophic changes. The transformation zone may be less accessible. This can lead to unsatisfactory tests or missed lesions.
HPV testing looks for viral DNA or RNA rather than abnormal cells. That makes it less dependent on seeing cell changes under a microscope. For older women with difficult sampling, this can be valuable.
Still, cytology has not disappeared. In many programmes, HPV testing and cytology work together. HPV testing identifies risk. Cytology helps clarify what that risk looks like now.
Screening approach | Main strength | Main limitation |
Cytology alone | Detects abnormal cells directly | Lower sensitivity and harder sampling after menopause |
Clinician-collected HPV testing | High sensitivity and strong reassurance when negative | Requires pelvic examination |
Self-collected HPV testing | Improves access and acceptability | Positive results need reliable follow-up |
HPV testing with cytology triage | Balances sensitivity with risk sorting | Needs coordinated lab and clinical pathways |
For women over 65, the best approach often depends less on the test alone and more on the pathway around it. A well-designed pathway answers three questions clearly:
Who should be screened after 65?
What happens after a positive HPV result?
How will the system support women through follow-up?
Tailored screening is the key for women 65 and older
Tailored screening means matching the method and interval to a woman’s risk, history, comfort, and ability to complete care. This is especially important after 65 because older women are not one uniform group.
A healthy 66-year-old with no prior records needs a different plan from a 72-year-old with three documented negative HPV tests and no history of precancer. A 69-year-old who cannot tolerate a speculum examination may benefit from self-sampling. A woman with previous high-grade changes may need continued surveillance even when others her age can stop.
A tailored plan should include the following elements.
Screening history should guide the decision
The safest exit from screening depends on documented negative tests. If records are missing, clinicians may treat the person as under-screened and offer HPV-based testing.
This is especially relevant in places where many women have not had regular screening throughout adulthood. In India and similar settings, lifetime screening coverage has often been uneven, with differences by region, income, education, and access to healthcare. Age alone should not be used to assume low risk.
The sampling method should respect comfort and access
Some older women prefer clinician collection because it feels more complete and allows a pelvic examination if needed. Others prefer self-sampling because it is private and less uncomfortable.
Both options can be valid when the test is approved for that collection method. Choice can improve participation, especially when instructions are simple and available in local languages.
Positive results need calm and clear follow-up
A positive HPV result can cause anxiety, particularly when someone has not been screened for many years. Clear counselling helps. The message should be direct: HPV positivity means a virus linked with cervical cancer risk was found, not that cancer was found.
Follow-up may include repeat HPV testing, cytology, HPV genotyping, colposcopy, or biopsy. The exact step depends on the result, the test used, prior history, and local guidelines.
Health status should be part of the plan
Screening should offer more benefit than harm. For women with serious illness or limited life expectancy, routine screening may not help and may lead to stressful procedures. For active older women with many healthy years ahead, screening may be valuable if risk is uncertain.
This is where shared decision-making matters. Good care does not simply apply an age cut-off. It weighs benefit, burden, and personal values.
What a practical screening pathway can look like
A practical strategy for women aged 65 and older could look like this:
Check whether the cervix is present
After hysterectomy, screening needs depend on whether the cervix was removed and why the surgery was done.
Review prior screening records
Documented negative HPV or co-test results may support stopping. Missing records may support continued testing.
Assess risk factors
Prior high-grade lesions, immunosuppression, and long gaps in screening raise concern.
Offer HPV-based testing when screening is indicated
Clinician-collected or self-collected sampling may be used if validated and available.
Use triage for HPV-positive results
Cytology, genotyping, repeat testing, or colposcopy can help avoid both overtreatment and missed disease.
Create a follow-up plan before testing
This includes how results will be shared, where follow-up will happen, and who will help if transport or cost is a barrier.
This type of pathway is simple but powerful. It avoids two common mistakes: stopping screening too early for women with unknown risk, and continuing screening automatically for women who have already met safe exit criteria.
The evidence points to choice, not a single rule
The strongest lesson from recent reviews is not that every woman over 65 needs the same test. It is that HPV-based screening gives a more sensitive way to identify risk, and self-sampling can bring testing to women who might otherwise be missed.
For older women, this matters because past screening histories vary widely. Some have decades of normal results and can safely exit. Others have never had a reliable chance to be screened. A fair screening strategy must recognise both realities.
The future of cervical cancer prevention for women 65 and older is likely to include:
HPV testing as the main risk-detection tool
Self-sampling for women who prefer it or face access barriers
Cytology and genotyping as triage tools
Clear exit criteria based on documented history
Follow-up systems that do not leave HPV-positive women unsupported
Age remains useful, but it should not do all the thinking. The better question is: what is this woman’s actual risk, and what screening method gives her the best chance of benefit with the least burden?
For women 65 and older, tailored HPV screening is not an extra layer of care. It is the safest way to make screening more accurate, more acceptable, and more equitable.
FOR OBGYN RECOMMENDATIONS & GUIDELINES:
Comments